Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aduhelm Approval Boosts Other Alzheimer’s Drug Developers

Even Companies Not Focused On Clearing Amyloid Benefitted

Executive Summary

Biogen/Eisai’s aducanumab, as the first disease-modifying therapy and setting a precedent for accelerated approval, lifted the entire Alzheimer’s field.

You may also be interested in...



IPO Update: Average Return Turns Negative For Newly Public Biopharma Firms

With 88 initial public offerings in the US through the end of the third quarter of 2021, the biopharma industry is two IPOs ahead of the full-year 2020 total, but with an average return of -4% momentum may slow.

Amylyx Will Submit ALS Drug For Approval In The Coming Months

After discussions with the US FDA, the company determined it can file AMX0035 based on Phase II/III results and interim Phase III data. Amylyx is sticking with its go-it-alone strategy for global commercialization.

Muna Launches On 'Rising Tide' Of Alzheimer's

Backed by investors such as Sofinnova, Polaris and Sanofi Ventures, Muna has assembled a strong team dedicated to developing small molecules to repair neuronal dysfunction and resolve neuroinflammation.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144494

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel